FSCN1

Summary

FSCN1 (fascin actin-bundling protein 1, HGNC:11148) is a protein-coding gene on chromosome 7p22.1, encoding Fascin (Q16658). Actin-binding protein that contains 2 major actin binding sites.

This gene encodes a member of the fascin family of actin-binding proteins. Fascin proteins organize F-actin into parallel bundles, and are required for the formation of actin-based cellular protrusions. The encoded protein plays a critical role in cell migration, motility, adhesion and cellular interactions. Expression of this gene is known to be regulated by several microRNAs, and overexpression of this gene may play a role in the metastasis of multiple types of cancer by increasing cell motility. Expression of this gene is also a marker for Reed-Sternberg cells in Hodgkin’s lymphoma. A pseudogene of this gene is located on the long arm of chromosome 15.

Source: NCBI Gene 6624 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 74 total — 1 likely-pathogenic
• Druggable target: yes
• MANE Select transcript: NM_003088

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11148
Approved symbol	FSCN1
Name	fascin actin-bundling protein 1
Location	7p22.1
Locus type	gene with protein product
Status	Approved
Aliases	p55, FLJ38511
Ensembl gene	ENSG00000075618
Ensembl biotype	protein_coding
OMIM	602689
Entrez	6624

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 6 protein_coding, 1 retained_intron

ENST00000382361, ENST00000405801, ENST00000444748, ENST00000447103, ENST00000473330, ENST00000905052, ENST00000905053

RefSeq mRNA: 1 — MANE Select: NM_003088 NM_003088

CCDS: CCDS5342

Canonical transcript exons

ENST00000382361 — 5 exons

Exon	Start	End
ENSE00001491843	5592816	5593768
ENSE00001812070	5605272	5606655
ENSE00003473601	5603863	5604030
ENSE00003495280	5603496	5603617
ENSE00003618745	5603257	5603413

Expression profiles

Bgee: expression breadth ubiquitous, 266 present calls, max score 98.64.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 150.2799 / max 1870.0761, expressed in 1789 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
77110	149.2378	1789
77112	0.7371	442
77113	0.3051	187

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	98.64	gold quality
ganglionic eminence	UBERON:0004023	98.51	gold quality
middle frontal gyrus	UBERON:0002702	98.43	gold quality
embryo	UBERON:0000922	98.40	gold quality
frontal pole	UBERON:0002795	98.23	gold quality
cortical plate	UBERON:0005343	98.19	gold quality
Brodmann (1909) area 10	UBERON:0013541	98.19	gold quality
prefrontal cortex	UBERON:0000451	97.05	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.82	gold quality
lower esophagus mucosa	UBERON:0035834	96.80	gold quality
ventricular zone	UBERON:0003053	96.60	gold quality
right frontal lobe	UBERON:0002810	96.16	gold quality
spinal cord	UBERON:0002240	96.00	gold quality
putamen	UBERON:0001874	95.73	gold quality
frontal cortex	UBERON:0001870	95.62	gold quality
amygdala	UBERON:0001876	95.59	gold quality
caudate nucleus	UBERON:0001873	95.34	gold quality
neocortex	UBERON:0001950	95.30	gold quality
cingulate cortex	UBERON:0003027	95.16	gold quality
anterior cingulate cortex	UBERON:0009835	95.12	gold quality
Brodmann (1909) area 9	UBERON:0013540	95.05	gold quality
nucleus accumbens	UBERON:0001882	95.00	gold quality
olfactory bulb	UBERON:0002264	94.74	gold quality
tendon of biceps brachii	UBERON:0008188	94.72	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	94.48	gold quality
telencephalon	UBERON:0001893	94.46	gold quality
cerebral cortex	UBERON:0000956	94.32	gold quality
postcentral gyrus	UBERON:0002581	94.02	gold quality
Ammon’s horn	UBERON:0001954	94.01	gold quality
tibial nerve	UBERON:0001323	93.78	gold quality

Single-cell (SCXA)

Detected in 16 experiment(s), a significant marker in 13.

Experiment	Marker?	Max mean expression
E-GEOD-139324	yes	1600.76
E-HCAD-8	yes	1178.73
E-MTAB-7381	yes	745.01
E-MTAB-6701	yes	51.16
E-HCAD-6	yes	41.04
E-GEOD-134144	yes	39.56
E-HCAD-10	yes	31.97
E-MTAB-8142	yes	27.28
E-CURD-46	yes	23.34
E-MTAB-8271	yes	14.99
E-MTAB-8498	yes	12.01
E-ANND-3	yes	9.27
E-CURD-112	yes	8.97
E-MTAB-7037	no	332.50
E-GEOD-81383	no	28.14

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AHR, CREB1, CTNNB1, HIF1A, HNF4A, NFKB, SMAD4, SP1, STAT1, STAT3

miRNA regulators (miRDB)

96 targeting FSCN1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-3663-3P	99.84	70.39	798
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-3150A-3P	99.76	64.44	1640
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-149-3P	99.72	68.22	3963

Literature-anchored findings (GeneRIF, showing 40)

• fascin is expressed in cutaneous CD30+ lymphoproliferative disorders and that it is a candidate marker of disease progression (PMID:12100631)
• Fascin is upregulated in invasive and more aggressive NSCLC, being an independent prognostic predictor of unfavourable clinical course of the disease (PMID:12592367)
• Fascin regulatory sequences are found solely in the 5’-flanking promoter region; the promoter exerts robust activity in dendritic cells (DC) and a fascin-positive neuronal cell line; promoter activity in DC markedly increases with maturation of DC. (PMID:12902483)
• Fascin-1 plays an essential role in polarity of actin bundles in filopodia. In the in vitro motility assay, actin/fascin bundles slid as fast as single actin filaments on myosin II and myosin V (PMID:14535950)
• fascin is an actin-bundling motility protein with a role in progression of hormone receptor-negative breast cancer (PMID:15671545)
• In conclusion, this research supports FSCN1 as a novel marker of NT2 neuronal differentiation and the possible role of CBP in its regulation. (PMID:15882811)
• Over expression of fascin is associated with basal-like phenotype and BRCA1-associated node-negative invasive breast carcinomas (PMID:16533778)
• Higher fascin scores in fascin in renal cell carcinoma were significantly correlated with higher T and N stages and nuclear grade (PMID:16977579)
• Fascin is upregulated in a proportion of adenomas, where its expression is often focal. Fascin may have prognostic value as an early biomarker for more aggressive colorectal adenocarcinomas. (PMID:17029629)
• LXR is a potent modulator of dendritic cells maturation and function mediated in part by blocking the expression of fascin. (PMID:17255360)
• Higher expression of fascin-1 correlates significantly with tumor grades and stages in colorectal adenocarcinomas. (PMID:17473384)
• Higher intensity of cortactin and fascin-1 staining correlated directly with more-advanced cancer stages (TNM) and inversely with survival rates. (PMID:17510372)
• Fascin is a novel target of beta-catenin-TCF signaling and is expressed at the invasive front of human colon cancer (PMID:17638895)
• Analysis of fascin bundling indicated that filopodia are semiordered bundles with one bound fascin per 25-60 actin monomers. (PMID:17671164)
• This study demonstrates a role for fascin in glioma cell morphology, motility, and invasiveness. (PMID:18283337)
• Fascin may be a novel marker to distinguish thyroid carcinoma from benign lesions (PMID:18343949)
• The fascin-1 expression did not correlate with the depth of tumor invasion or with the urinary bladder tumor recurrence or progression. (PMID:18587253)
• Myosin X filopodial localization is perturbed in fascin-depleted HeLa cells, demonstrating that fascin bundles also direct motility in vivo. (PMID:18599451)
• Rac regulates the interaction of fascin with active PKC. (PMID:18716283)
• Cortactin, fascin-1 and EGFR have roles in progression of ovarian carcinomas (PMID:18776588)
• Expression of EBV LMP1 is positively correlated with Fascin, pStat3 and the proliferation index of tumor cells in nasopharyngeal carcinoma. (PMID:18851787)
• Fascin overexpression may be a marker of aggressive urothelial carcinomas. (PMID:19061289)
• Intense and strong fascin staining is found granulosa cell tumor adult type (AGCT);of fascin should question a provisional morphologic diagnosis of AGCT. (PMID:19115695)
• Cadherin-11 and fascin might be useful markers for recurrence of pleomorphic adenomas. (PMID:19133007)
• data identify novel roles for CREB and AhR as major, specific regulators of FSCN-1 transcription in human carcinoma cells but do not support the hypothesis that beta-catenin signaling has a central role (PMID:19340314)
• Fascin can serve as a reliable immunohistochemical marker in distinguishing uterine leiomyosarcoma from leiomyoma variants and usual leiomyoma (PMID:19483633)
• High fascin expression is significantly correlated with aggressive tumor phenotype in extrahepatic bile duct carcinoma and is an independent poor prognostic factor in extrahepatic bile duct carcinoma. (PMID:19556073)
• Study found that ERK and JNK pathways are involved in TGF-b1-induced fascin1 expression in the human gastric cancer cell line MKN45. (PMID:19657566)
• Overexpression of fascin may have an important function in the progression of cholangiocarcinoma. (PMID:19721413)
• study found that Rab35 regulates the assembly of actin filaments in filopodia formation; effect was mediated by the actin-bundling protein fascin, which directly associated with active Rab35 (PMID:19729655)
• fascin is overexpressed in colorectal adenomas and promotes motility in adenoma cells in vitro. (PMID:19738613)
• Simultaneous analyses of fascin-1 and E-cadherin expression could be more effective in evaluating the prognoses of patients with laryngeal squamous cell carcinoma. (PMID:19741544)
• High expression level of fascin1 was associated with nasopharyngeal carcinoma aggressiveness. (PMID:19759191)
• Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. (PMID:19818782)
• fascin1 plays a significant role in non-small cell lung cancer metastasis (PMID:19819618)
• Down-regulation of fascin1 suppresses the proliferation and migration of gastric cancer cells MKN45. (PMID:20001345)
• Fascin regulates the proliferation and invasiveness of ESCC cells by modulating the expression of CTGF and CYR61 via TGF-beta pathway. (PMID:20056838)
• The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. (PMID:20137952)
• The mechanism of bundling of cytoskeletal actin filaments by two representative bundling proteins, fascin and espin, was examined. (PMID:20366178)
• The structure reveals a novel arrangement of four tandem beta-trefoil domains that form a bi-lobed structure with approximate pseudo 2-fold symmetry. (PMID:20434460)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	fscn1a	ENSDARG00000059680
mus_musculus	Fscn1	ENSMUSG00000029581
rattus_norvegicus	Fscn1	ENSRNOG00000056585
drosophila_melanogaster	sn	FBGN0003447

Paralogs (2): FSCN3 (ENSG00000106328), FSCN2 (ENSG00000186765)

Protein

Protein identifiers

Fascin — Q16658 (reviewed: Q16658)

Alternative names: 55 kDa actin-bundling protein, Singed-like protein, p55

All UniProt accessions (5): Q16658, A0A0A0MSB2, A0A384MEG1, C9JFC0, C9JPH9

UniProt curated annotations — full annotation on UniProt →

Function. Actin-binding protein that contains 2 major actin binding sites. Organizes filamentous actin into parallel bundles. Plays a role in the organization of actin filament bundles and the formation of microspikes, membrane ruffles, and stress fibers. Important for the formation of a diverse set of cell protrusions, such as filopodia, and for cell motility and migration. Mediates reorganization of the actin cytoskeleton and axon growth cone collapse in response to NGF.

Subunit / interactions. Interacts with RUFY3 (via N-terminus); the interaction induces neuron axon development. Interacts with NGFR. Associates with CTNNB1. Interacts with PLXNB3.

Subcellular location. Cytoplasm. Cytosol. Cell cortex. Cytoskeleton. Stress fiber. Cell projection. Filopodium. Invadopodium. Microvillus. Cell junction.

Tissue specificity. Ubiquitous.

Post-translational modifications. Phosphorylation at Ser-39 inhibits actin-binding. Phosphorylation is required for the reorganization of the actin cytoskeleton in response to NGF.

Domain organisation. Composed of four fascin beta-trefoil domains.

Similarity. Belongs to the fascin family.

RefSeq proteins (1): NP_003079* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008999	Actin-crosslinking	Homologous_superfamily
IPR010431	Fascin	Family
IPR022768	Fascin-like_dom	Domain
IPR024703	Fascin_metazoans	Family

Pfam: PF06268

UniProt features (110 total): strand 54, mutagenesis site 25, helix 12, modified residue 8, turn 7, initiator methionine 1, chain 1, cross-link 1, sequence conflict 1

Structure

Experimental structures (PDB)

28 structures.

PDB	Method	Resolution (Å)
6I18	X-RAY DIFFRACTION	1.49
6I17	X-RAY DIFFRACTION	1.56
6I12	X-RAY DIFFRACTION	1.65
6I11	X-RAY DIFFRACTION	1.67
6I14	X-RAY DIFFRACTION	1.73
6I0Z	X-RAY DIFFRACTION	1.77
6I13	X-RAY DIFFRACTION	1.79
3LLP	X-RAY DIFFRACTION	1.8
6I15	X-RAY DIFFRACTION	1.91
9GS6	X-RAY DIFFRACTION	1.97
3P53	X-RAY DIFFRACTION	2
6I16	X-RAY DIFFRACTION	2
6I10	X-RAY DIFFRACTION	2.1
4GOV	X-RAY DIFFRACTION	2.2
7ZAU	X-RAY DIFFRACTION	2.2
9FN6	X-RAY DIFFRACTION	2.2
4GP3	X-RAY DIFFRACTION	2.25
4GOY	X-RAY DIFFRACTION	2.3
4GP0	X-RAY DIFFRACTION	2.5
6B0T	X-RAY DIFFRACTION	2.8
1DFC	X-RAY DIFFRACTION	2.9
8VO5	ELECTRON MICROSCOPY	3
8VO6	ELECTRON MICROSCOPY	3.1
8VO7	ELECTRON MICROSCOPY	3.1
8VO9	ELECTRON MICROSCOPY	3.4
8VO8	ELECTRON MICROSCOPY	3.9
8VOA	ELECTRON MICROSCOPY	4
9GXI	ELECTRON MICROSCOPY	9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q16658-F1	94.45	0.92

Antibody-complex structures (SAbDab): 1 — 7ZAU

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (9): 399, 2, 38, 39, 74, 127, 234, 239, 403

Mutagenesis-validated functional residues (25):

Position	Phenotype
22	decreased actin-binding and loss of actin-bundling activity; when associated with e-43 and e-398. decreased actin-bindin
29	strongly decreases actin-bundling activity.
36–39	abolishes axon growth cone collapse in response to ngf.
39	loss of phosphorylation.
39	phosphomimetic mutant that strongly decreases actin-bundling activity.
43	decreased actin-binding and loss of actin-bundling activity; when associated with e-22 and e-398. decreased actin-bindin
49	strongly decreases actin-bundling activity.
100	mildly decreased actin-binding and actin-bundling activity; when associated with e-109 and e-247. decreased actin-bindin
109	mildly decreased actin-binding and actin-bundling activity; when associated with e-100 and e-247. decreased actin-bindin
149–151	strongly decreases actin-bundling activity.
150–151	no significant effect on actin-binding and actin-bundling activity; when associated with e-313.
247–250	decreases actin-bundling activity.
247	mildly decreased actin-binding and actin-bundling activity; when associated with e-100 and e-109.
271	decreased actin-binding and actin-bundling activity; when associated with e-353 and e-358.
313	no significant effect on actin-binding and actin-bundling activity; when associated with 150-e-e-151.
341	no significant effect on actin-binding and actin-bundling activity; when associated with e-348 and q-464.
348	no significant effect on actin-binding and actin-bundling activity; when associated with e-341 and q-464.
353	decreased actin-binding and actin-bundling activity; when associated with e-271 and e-358.
358	strongly decreases actin-bundling activity.
358	decreased actin-binding and actin-bundling activity; when associated with e-271 and e-353.
392	decreased actin-bundling activity.
398	decreased actin-binding and loss of actin-bundling activity; when associated with e-22 and e-43.
464	no significant effect on actin-binding and actin-bundling activity; when associated with e-341 and e-348.
471	decreased actin-bundling activity.
488	decreased actin-bundling activity.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling

MSigDB gene sets: 374 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_UP, GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, BORCZUK_MALIGNANT_MESOTHELIOMA_UP, GOBP_ESTABLISHMENT_OR_MAINTENANCE_OF_MONOPOLAR_CELL_POLARITY, WANG_CLIM2_TARGETS_UP, GOBP_ACTIN_FILAMENT_BUNDLE_ORGANIZATION, GOBP_ESTABLISHMENT_OR_MAINTENANCE_OF_CELL_POLARITY, GOBP_REGULATION_OF_PODOSOME_ASSEMBLY, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, YANG_BREAST_CANCER_ESR1_LASER_DN, GOCC_RUFFLE, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_REGULATION_OF_LAMELLIPODIUM_ASSEMBLY, GOBP_REGULATION_OF_EXTRACELLULAR_MATRIX_ORGANIZATION

GO Biological Process (16): cell-cell junction assembly (GO:0007043), establishment or maintenance of cell polarity (GO:0007163), positive regulation of lamellipodium assembly (GO:0010592), cell migration (GO:0016477), microspike assembly (GO:0030035), actin cytoskeleton organization (GO:0030036), parallel actin filament bundle assembly (GO:0030046), regulation of microvillus assembly (GO:0032534), regulation of actin cytoskeleton organization (GO:0032956), establishment of apical/basal cell polarity (GO:0035089), cell motility (GO:0048870), actin filament bundle assembly (GO:0051017), positive regulation of filopodium assembly (GO:0051491), positive regulation of podosome assembly (GO:0071803), positive regulation of extracellular matrix disassembly (GO:0090091), actin filament organization (GO:0007015)

GO Molecular Function (6): RNA binding (GO:0003723), actin binding (GO:0003779), protein-macromolecule adaptor activity (GO:0030674), cadherin binding (GO:0045296), actin filament binding (GO:0051015), protein binding (GO:0005515)

GO Cellular Component (19): stress fiber (GO:0001725), ruffle (GO:0001726), podosome (GO:0002102), cytoplasm (GO:0005737), cytosol (GO:0005829), cytoskeleton (GO:0005856), microvillus (GO:0005902), cell-cell junction (GO:0005911), cell cortex (GO:0005938), actin cytoskeleton (GO:0015629), lamellipodium (GO:0030027), filopodium (GO:0030175), growth cone (GO:0030426), cell projection membrane (GO:0031253), microspike (GO:0044393), extracellular exosome (GO:0070062), cell leading edge (GO:0031252), cell projection (GO:0042995), anchoring junction (GO:0070161)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Signaling by Interleukins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
plasma membrane bounded cell projection	4
cellular anatomical structure	4
positive regulation of plasma membrane bounded cell projection assembly	3
actin-based cell projection	3
cellular process	2
actin cytoskeleton organization	2
cell leading edge	2
cytoplasm	2
cell junction assembly	1
cell-cell junction organization	1
regulation of lamellipodium assembly	1
lamellipodium assembly	1
positive regulation of lamellipodium organization	1
cell motility	1
plasma membrane bounded cell projection assembly	1
cytoskeleton organization	1
actin filament-based process	1
actin filament bundle assembly	1
microvillus assembly	1
regulation of microvillus organization	1
regulation of plasma membrane bounded cell projection assembly	1
regulation of actin filament-based process	1
regulation of cytoskeleton organization	1
establishment or maintenance of apical/basal cell polarity	1
establishment of monopolar cell polarity	1
cellular component assembly	1
actin filament bundle organization	1
filopodium assembly	1
regulation of filopodium assembly	1
positive regulation of protein-containing complex assembly	1
podosome assembly	1
regulation of podosome assembly	1
regulation of extracellular matrix disassembly	1
extracellular matrix disassembly	1
positive regulation of extracellular matrix organization	1
supramolecular fiber organization	1
nucleic acid binding	1
cytoskeletal protein binding	1
protein binding	1
molecular adaptor activity	1

Protein interactions and networks

STRING

2132 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FSCN1	ESPN	B1AK53	942
FSCN1	FLNA	P21333	863
FSCN1	RAB35	Q15286	853
FSCN1	CTNNB1	P35222	846
FSCN1	ANGPTL4	Q9BY76	841
FSCN1	LCP1	P13796	811
FSCN1	WASL	O00401	786
FSCN1	FLNB	O75369	783
FSCN1	FLNC	Q14315	779
FSCN1	PLS1	Q14651	777
FSCN1	DMTN	Q08495	768
FSCN1	ACTN4	O43707	767
FSCN1	CFL1	P23528	765
FSCN1	HCLS1	P14317	763
FSCN1	CTTN	Q14247	763

IntAct

122 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
FANCD2	FSCN1	psi-mi:“MI:0915”(physical association)	0.650
FSCN1	FANCD2	psi-mi:“MI:0915”(physical association)	0.650
FSCN1	FANCD2	psi-mi:“MI:0403”(colocalization)	0.650
CFTR	HAX1	psi-mi:“MI:0914”(association)	0.610
FSCN1	MLH1	psi-mi:“MI:0914”(association)	0.600
MLH1	FSCN1	psi-mi:“MI:0915”(physical association)	0.600
FSCN1	YWHAZ	psi-mi:“MI:0915”(physical association)	0.560
STAT3	CLIC1	psi-mi:“MI:0914”(association)	0.530
VCAM1	PSMD11	psi-mi:“MI:0914”(association)	0.530
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
MYO10	FSCN1	psi-mi:“MI:0915”(physical association)	0.400
FSCN1	H2BC21	psi-mi:“MI:0915”(physical association)	0.400
Pafah1b1	EDIL3	psi-mi:“MI:0915”(physical association)	0.400
Sass6		psi-mi:“MI:0915”(physical association)	0.400
RB1	FSCN1	psi-mi:“MI:0915”(physical association)	0.400
FSCN1	PLXNB3	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (323): ASS1 (Co-fractionation), COTL1 (Co-fractionation), CRYZ (Co-fractionation), FSCN1 (Co-fractionation), FSCN1 (Co-fractionation), FUBP1 (Co-fractionation), MIF (Co-fractionation), PCBP1 (Co-fractionation), PRDX1 (Co-fractionation), PRDX2 (Co-fractionation), TKT (Co-fractionation), FSCN1 (Affinity Capture-MS), FSCN1 (Affinity Capture-MS), FSCN1 (Affinity Capture-MS), FSCN1 (Affinity Capture-MS)

ESM2 similar proteins: B0LPN4, E9PZQ0, E9Q401, F1LMY4, O14926, O18728, O95834, P10767, P11403, P11716, P16960, P21658, P21817, P30957, P47823, P55075, P85845, Q13144, Q16658, Q24498, Q24524, Q32M02, Q3U7R1, Q4R4H3, Q5CZL1, Q5E9M9, Q5XGM5, Q61553, Q64350, Q6P6T4, Q6P9Z4, Q6PFQ7, Q6SZW1, Q7TNG5, Q7TSA0, Q7Z6L1, Q8CHW4, Q8IXI1, Q8JZN7, Q8K2J0

Diamond homologs: O14926, O18728, P85845, Q16658, Q24524, Q32M02, Q61553, Q91837, Q05634

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
PRKCD	“down-regulates activity”	FSCN1	phosphorylation
PLXNB3	“up-regulates activity”	FSCN1
FSCN1	up-regulates	Actin_cytoskeleton_reorganization

Disease & clinical

Clinical variants and AI predictions

ClinVar

74 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	66
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
146321	GRCh38/hg38 7p22.1(chr7:5578185-5775451)x1	Likely pathogenic

SpliceAI

807 predictions. Top by Δscore:

Variant	Effect	Δscore
7:5593767:GG:G	donor_gain	1.0000
7:5593768:GG:G	donor_gain	1.0000
7:5603252:TGCA:T	acceptor_loss	1.0000
7:5603253:GCAG:G	acceptor_loss	1.0000
7:5603254:CA:C	acceptor_loss	1.0000
7:5603255:A:T	acceptor_loss	1.0000
7:5603256:GGT:G	acceptor_gain	1.0000
7:5603256:GGTAT:G	acceptor_gain	1.0000
7:5603410:GCAA:G	donor_gain	1.0000
7:5603411:CAAG:C	donor_loss	1.0000
7:5603413:AGTG:A	donor_loss	1.0000
7:5603414:G:GG	donor_gain	1.0000
7:5603414:GTG:G	donor_loss	1.0000
7:5603491:CCCA:C	acceptor_loss	1.0000
7:5603492:CCA:C	acceptor_loss	1.0000
7:5603494:A:AG	acceptor_gain	1.0000
7:5603494:A:T	acceptor_loss	1.0000
7:5603494:AG:A	acceptor_gain	1.0000
7:5603495:G:A	acceptor_loss	1.0000
7:5603495:G:GA	acceptor_gain	1.0000
7:5603495:GG:G	acceptor_gain	1.0000
7:5603495:GGA:G	acceptor_gain	1.0000
7:5603495:GGAA:G	acceptor_gain	1.0000
7:5603495:GGAAT:G	acceptor_gain	1.0000
7:5603613:AGCAG:A	donor_loss	1.0000
7:5603614:GCAG:G	donor_gain	1.0000
7:5603615:CAGG:C	donor_loss	1.0000
7:5603617:GGT:G	donor_loss	1.0000
7:5603618:GT:G	donor_loss	1.0000
7:5603619:T:G	donor_loss	1.0000

AlphaMissense

3244 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:5593021:T:C	F29L	1.000
7:5593023:C:A	F29L	1.000
7:5593023:C:G	F29L	1.000
7:5593072:T:A	W46R	1.000
7:5593072:T:C	W46R	1.000
7:5593330:T:A	W132R	1.000
7:5593330:T:C	W132R	1.000
7:5593604:T:C	F223S	1.000
7:5593640:G:A	G235E	1.000
7:5603367:T:A	W315R	1.000
7:5603367:T:C	W315R	1.000
7:5603588:G:A	G361E	1.000
7:5592980:G:A	G15D	0.999
7:5592983:T:C	L16P	0.999
7:5593003:T:C	Y23H	0.999
7:5593003:T:G	Y23D	0.999
7:5593007:T:C	L24P	0.999
7:5593013:C:A	A26D	0.999
7:5593021:T:A	F29I	0.999
7:5593022:T:C	F29S	0.999
7:5593022:T:G	F29C	0.999
7:5593057:A:G	K41E	0.999
7:5593059:G:C	K41N	0.999
7:5593059:G:T	K41N	0.999
7:5593068:G:C	Q44H	0.999
7:5593068:G:T	Q44H	0.999
7:5593073:G:C	W46S	0.999
7:5593126:A:C	S64R	0.999
7:5593128:C:A	S64R	0.999
7:5593128:C:G	S64R	0.999

dbSNP variants (sampled 300 via entrez): RS1000030171 (7:5591485 G>A,C,T), RS1000420210 (7:5596098 G>A,C,T), RS1000716134 (7:5604394 C>T), RS1001404577 (7:5606568 G>C), RS1001440092 (7:5592706 G>C,T), RS1001772445 (7:5606317 A>C), RS1002209355 (7:5602134 G>A,C,T), RS1002360285 (7:5597218 A>G), RS1002369215 (7:5592470 G>A), RS1002421479 (7:5592663 G>A), RS1002489967 (7:5606691 G>A,C,T), RS1002499950 (7:5592739 G>A,C,T), RS1002882835 (7:5604156 A>G), RS1002889538 (7:5598855 G>A), RS1002981356 (7:5599037 G>C)

Disease associations

OMIM: gene MIM:602689 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523304 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

30 measured of 30 human assays (30 total across all organisms); most potent 30 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
(Z)-N-(2,3-diphenyl-1,2,4- thiadiazol-5(2H)- ylidene)methanamine	IC50	500 nM	US-10208043: Methods for inhibiting fascin
N-(3-(1H-1,2,4-triazol-3- ylthio)-4- hydroxynaphthalen-1-yl)- 2,4,5-trimethyl- benzenesulfonamide	IC50	539 nM	US-10208043: Methods for inhibiting fascin
2-chloro-N-(6- chlorobenzo[d]thiazol-2- yl)-5- nitrobenzenesulfonamide	IC50	652 nM	US-10208043: Methods for inhibiting fascin
N-(3-(1H-1,2,4-triazol-3- ylthio)-4- hydroxynaphthalen-1-yl)- 2,5-dimethyl- benzenesulfonamide	IC50	683 nM	US-10208043: Methods for inhibiting fascin
5-(3,4-dichlorobenzyl)-1- (S,S,-dioxo- tetrahydrothiophen-3-yl)- 1H-pyrazol[3,4- d]pyrimidin-4(5H)-one	IC50	734 nM	US-10208043: Methods for inhibiting fascin
N-(3-(1H-1,2,4-triazol-3- ylthio)-4- hydroxynaphthalen-1-yl)- 4-methoxy- benzenesulfonamide	IC50	807 nM	US-10208043: Methods for inhibiting fascin
N-(3-(1H-1,2,4-triazol-3- ylthio)-4- hydroxynaphthalen-1-yl)- 4-ethyl- benzenesulfonamide	IC50	890 nM	US-10208043: Methods for inhibiting fascin
5-(3-chlorobenzyl)-1-(2- hydroxyethyl)-1H- pyrazol[3,4-d]pyrimidin- 4(5H)-one	IC50	1200 nM	US-10208043: Methods for inhibiting fascin
N-(3-(1H-1,2,4-triazol-3- ylthio)-4- hydroxynaphthalen-1- yl)-4- ethoxybenzenesulfonamide	IC50	1470 nM	US-10208043: Methods for inhibiting fascin
N-(1-(4- (trifluoromethyl)benzyl)- 1H-indazol-3-yl)furan-2- carboxamide	IC50	2000 nM	US-10208043: Methods for inhibiting fascin
N-phenyl-2,3-diphenyl- 1,2,4-thiadiazolium-5- amine	IC50	2000 nM	US-10208043: Methods for inhibiting fascin
(Z)-N-(3-(1H-1,2,4-triazol- 3-ylthio)-4-oxonaphthalen- 1(4H)-ylidene) benzenesulfonamide	IC50	2000 nM	US-10208043: Methods for inhibiting fascin
N-(6- chlorobenzo[d]thiazol-2- yl)acetamide	IC50	2000 nM	US-10208043: Methods for inhibiting fascin
5-(3,4-dichlorobenzyl)-1- o-tolyl-1H-pyrazolo[3,4- d]pyrimidin-4(5H)-one	IC50	2000 nM	US-10208043: Methods for inhibiting fascin
5-(3,4-dichlorobenzyl)-1- (2,4-dimethylphenyl)-1H- pyrazolo[3,4-d]pyrimidin- 4(5H)-one	IC50	2100 nM	US-10208043: Methods for inhibiting fascin
5-(3,4-dichlorobenzyl)-1- (2,3-dimethylphenyl)-1H- pyrazolo[3,4-d]pyrimidin- 4(5H)-one	IC50	2300 nM	US-10208043: Methods for inhibiting fascin
4-bromo-N-[4-hydroxy-3-(1H-1,2,4-triazol-5-ylsulfanyl)naphthalen-1-yl]benzenesulfonamide	IC50	2620 nM	US-10208043: Methods for inhibiting fascin
N-(3-(1H-1,2,4-triazol-3- ylthio)-4- hydroxynaphthalen-1-yl)- 2,4-dimethyl- benzenesulfonamide	IC50	2700 nM	US-10208043: Methods for inhibiting fascin
2-(4-oxo-1-(S,S,-dioxo- tetrahydrothiophen-3-yl)- 1H-pyrazolo[3,4-d] pyrimidin-5(4H)-yl)-N- (3-(trifluoromethyl) phenyl)acetamide	IC50	3400 nM	US-10208043: Methods for inhibiting fascin
5-(2-(benzo[d][1,3]dioxol- 5-yl)-2-oxoethyl)-1-(S,S- dioxo-tetrahydrothiophen- 3-yl)-1H-pyrazolo[3,4- d]pyrimidin-4(5H)-one	IC50	3700 nM	US-10208043: Methods for inhibiting fascin
3-chloro-N-(6- phenoxybenzo[d]thiazol-2- yl)benzenesulfonamide	IC50	4000 nM	US-10208043: Methods for inhibiting fascin
N-(6- fluorobenzo[d]thiazol-2- yl)-3-nitro- benzenesulfonamide	IC50	4000 nM	US-10208043: Methods for inhibiting fascin
N-(benzo[d]thiazol-2- yl)cinnamamide	IC50	4000 nM	US-10208043: Methods for inhibiting fascin
N-(4-fluorobenzyl)-2-(4- oxo-1-(S,S-dioxo- tetrahydrothiophen-3-yl)- 1H-pyrazolo[3,4- d]pyrimidin-5(4H)- yl)acetamide	IC50	4300 nM	US-10208043: Methods for inhibiting fascin
N-(4-chlorophenyl)-2-(4- oxo-1-(S,S-dioxo- tetrahydrothiophen-3-yl)- 1H-pyrazolo[3,4- d]pyrimidin-5(4H)- yl)acetamide	IC50	4300 nM	US-10208043: Methods for inhibiting fascin
N-(benzo[d][1,3]dioxol-5- ylmethyl)-2-(4-oxo-1-(S,S- dioxo-tetrahydrothiophen- 3-yl)-1H-pyrazolo[3,4- d]pyrimidin-5(4H)- yl)acetamide	IC50	4600 nM	US-10208043: Methods for inhibiting fascin
5-(2-(2,4-dimethylphenyl)- 2-oxoethyl)-1-(S,S-dioxo- tetrahydrothiophen-3-yl)- 1H-pyrazolo[3,4- d]pyrimidin-4(5H)-one	IC50	4700 nM	US-10208043: Methods for inhibiting fascin
N-benzyl-2,3-diphenyl- 1,2,4-thiadiazolium-5- amine	IC50	5000 nM	US-10208043: Methods for inhibiting fascin
5-(2-(2,3- dihydrobenzo[b][1,4]dioxin- 6-yl)-2-oxoethyl)-1-(S,S- dioxo-tetrahydrothiophen- 3-yl)-1H-pyrazolo[3,4- d]pyrimidin-4(5H)-one	IC50	10000 nM	US-10208043: Methods for inhibiting fascin
2,3-dichloro-N-(6- fluorobenzo[d]thiazol-2- yl)benzenesulfonamide	IC50	13000 nM	US-10208043: Methods for inhibiting fascin

ChEMBL bioactivities

93 potent at pChembl≥5 of 105 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.73	Kd	18.56	nM	CHEMBL3752910
7.73	ED50	18.56	nM	CHEMBL3752910
7.30	Kd	50	nM	CHEMBL4452711
7.05	Kd	90	nM	CHEMBL4452711
6.62	IC50	240	nM	CHEMBL4452711
6.60	Kd	250	nM	CHEMBL4574198
6.57	Kd	270	nM	CHEMBL4461540
6.48	IC50	330	nM	CHEMBL4461540
6.46	Kd	348.5	nM	CHEMBL5653589
6.46	ED50	348.5	nM	CHEMBL5653589
6.30	IC50	500	nM	CHEMBL1188627
6.30	IC50	500	nM	CHEMBL3559101
6.30	IC50	500	nM	CHEMBL5937146
6.29	IC50	510	nM	CHEMBL4574198
6.27	IC50	539	nM	CHEMBL3235902
6.24	Kd	580	nM	CHEMBL4559691
6.22	Kd	600	nM	CHEMBL4566108
6.20	IC50	630	nM	CHEMBL4559691
6.20	IC50	630	nM	CHEMBL4566108
6.19	IC50	652	nM	CHEMBL4539339
6.17	IC50	683	nM	CHEMBL4526942
6.13	IC50	734	nM	CHEMBL4440859
6.09	IC50	807	nM	CHEMBL1540929
6.05	IC50	890	nM	CHEMBL4524644
5.99	Kd	1030	nM	CHEMBL4472315
5.96	Kd	1100	nM	CHEMBL4470509
5.92	Kd	1200	nM	CHEMBL4457641
5.92	IC50	1200	nM	CHEMBL4549117
5.89	Kd	1300	nM	CHEMBL4516481
5.89	IC50	1300	nM	CHEMBL4451624
5.83	IC50	1470	nM	CHEMBL3235888
5.82	Kd	1500	nM	CHEMBL4451624
5.80	Kd	1600	nM	CHEMBL4584583
5.70	Kd	2000	nM	CHEMBL4539975
5.70	IC50	2000	nM	CHEMBL4554206
5.70	IC50	2000	nM	CHEMBL1740740
5.70	IC50	2000	nM	CHEMBL4569970
5.70	IC50	2000	nM	CHEMBL4556783
5.70	IC50	2000	nM	CHEMBL4553279
5.70	IC50	2000	nM	CHEMBL5919648
5.70	IC50	2000	nM	CHEMBL6035746
5.68	IC50	2100	nM	CHEMBL4457641
5.68	IC50	2100	nM	CHEMBL4580744
5.64	IC50	2300	nM	CHEMBL4582975
5.58	IC50	2620	nM	CHEMBL3235887
5.57	Kd	2700	nM	CHEMBL4564438
5.57	Kd	2700	nM	CHEMBL4544795
5.57	IC50	2700	nM	CHEMBL590438
5.47	IC50	3400	nM	CHEMBL4546807
5.43	IC50	3700	nM	CHEMBL4521764

PubChem BioAssay actives

31 with measured affinity, of 61 total; 19 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148400: Binding affinity to human FSCN1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0186	uM
5-[(3,4-dichlorophenyl)methyl]-4-oxo-1-piperidin-4-yl-N-pyridin-4-ylpyrazolo[4,5-c]pyridine-7-carboxamide	1602455: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by ITC	kd	0.0500	uM
2-[(3,4-dichlorophenyl)methyl]-N-(1-methylpyrazol-4-yl)-1-oxo-6-piperidin-1-yl-2,7-naphthyridine-4-carboxamide	1602454: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by SPR assay	kd	0.2500	uM
5-[(3,4-dichlorophenyl)methyl]-1-(1,1-dioxothiolan-3-yl)-4-oxo-N-pyridin-4-ylpyrazolo[4,5-c]pyridine-7-carboxamide	1602454: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by SPR assay	kd	0.2700	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148400: Binding affinity to human FSCN1 incubated for 45 mins by Kinobead based pull down assay	kd	0.3485	uM
2-[(3,4-dichlorophenyl)methyl]-N-(1-methylpyrazol-4-yl)-1-oxo-6-piperazin-1-yl-2,7-naphthyridine-4-carboxamide	1602454: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by SPR assay	kd	0.5800	uM
5-[(3,4-dichlorophenyl)methyl]-1-(1,1-dioxothiolan-3-yl)-N-(1-methylpyrazol-4-yl)-4-oxopyrazolo[4,5-c]pyridine-7-carboxamide	1602454: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by SPR assay	kd	0.6000	uM
2-[(3,4-dichlorophenyl)methyl]-N-(1-methylpyrazol-4-yl)-1-oxo-6-pyrrolidin-1-yl-2,7-naphthyridine-4-carboxamide	1602454: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by SPR assay	kd	1.0300	uM
2-[(3,4-dichlorophenyl)methyl]-6-(methylamino)-N-(1-methylpyrazol-4-yl)-1-oxo-2,7-naphthyridine-4-carboxamide	1602454: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by SPR assay	kd	1.1000	uM
2-[(3-chloro-4-fluorophenyl)methyl]-N-(1-methylpyrazol-4-yl)-1-oxoisoquinoline-4-carboxamide	1602454: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by SPR assay	kd	1.2000	uM
2-[(3,4-dichlorophenyl)methyl]-N-(1-methylpyrazol-4-yl)-1-oxoisoquinoline-4-carboxamide	1602453: Inhibition of human (His8)2-tagged fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS assessed as reduction in F-actin bundling preincubated for 30 mins followed by F-actin addition and measured after 45 mins by Coomassie blue staining-based SDS-PAGE analysis	ic50	1.3000	uM
2-[(3,4-dichlorophenyl)methyl]-N-(1-methylpyrazol-4-yl)-1-oxo-2,7-naphthyridine-4-carboxamide	1602454: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by SPR assay	kd	1.3000	uM
2-[(3,4-dichlorophenyl)methyl]-N-(1-methylpyrazol-4-yl)-1-oxo-2,6-naphthyridine-4-carboxamide	1602454: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by SPR assay	kd	1.6000	uM
2-[(3,4-dichlorophenyl)methyl]-6-[methyl(methylsulfonyl)amino]-N-(1-methylpyrazol-4-yl)-1-oxo-2,7-naphthyridine-4-carboxamide	1602454: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by SPR assay	kd	2.0000	uM
2-[(4-chlorophenyl)methyl]-N-(1-methylpyrazol-4-yl)-1-oxoisoquinoline-4-carboxamide	1602454: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by SPR assay	kd	2.7000	uM
2-[(4-fluorophenyl)methyl]-N-(1-methylpyrazol-4-yl)-1-oxoisoquinoline-4-carboxamide	1602454: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by SPR assay	kd	2.7000	uM
2-[(3-cyano-4-fluorophenyl)methyl]-N-(1-methylpyrazol-4-yl)-1-oxoisoquinoline-4-carboxamide	1602454: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by SPR assay	kd	6.6000	uM
2-[(3-chlorophenyl)methyl]-N-(1-methylpyrazol-4-yl)-1-oxoisoquinoline-4-carboxamide	1602454: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by SPR assay	kd	7.6000	uM
5-[(3,4-dichlorophenyl)methyl]-N-(1-methylpyrazol-4-yl)-4-oxo-1H-pyrazolo[4,5-c]pyridine-7-carboxamide	1602454: Binding affinity to human fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS by SPR assay	kd	10.0000	uM

CTD chemical–gene interactions

80 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Arsenic Trioxide	decreases expression, increases expression, affects binding, decreases reaction, increases reaction	5
Valproic Acid	affects expression, increases expression, increases methylation	5
bisphenol A	affects expression, decreases expression, increases expression	4
Cyclosporine	decreases expression	4
Estradiol	increases expression, decreases expression, affects cotreatment	3
Tretinoin	decreases expression	3
sodium arsenite	increases expression, affects expression	2
perfluorooctanoic acid	decreases expression	2
Cisplatin	affects cotreatment, increases expression	2
Lipopolysaccharides	decreases reaction, increases expression, affects expression, affects response to substance	2
Silicon Dioxide	affects secretion, increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Tunicamycin	decreases expression	2
Particulate Matter	decreases expression, increases abundance, affects cotreatment, increases expression	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
sotorasib	affects cotreatment, decreases expression	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
pyrogallol 1,3-dimethyl ether	increases expression, affects cotreatment, affects localization, decreases expression	1
trichostatin A	affects expression	1
cobaltous chloride	decreases expression	1
butyraldehyde	increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
quinoline	increases expression	1
pentanal	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
tebuconazole	decreases expression	1

ChEMBL screening assays

11 unique, capped per target: 11 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4401535	Binding	Inhibition of human (His8)2-tagged fascin (1 to 493 residues) expressed in Escherichia coli BL21(DE3) pLysS assessed as reduction in F-actin bundling preincubated for 30 mins followed by F-actin addition and measured after 45 mins by Coomas	Structure-based design, synthesis and biological evaluation of a novel series of isoquinolone and pyrazolo[4,3-c]pyridine inhibitors of fascin 1 as potential anti-metastatic agents. — Bioorg Med Chem Lett

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1DI	Abcam HCT 116 FSCN1 KO	Cancer cell line	Male
CVCL_E0DC	Ubigene HeLa FSCN1 KO	Cancer cell line	Female
CVCL_SN94	HAP1 FSCN1 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.